Yourgene Health plc
(“Yourgene” or the “Group”)
American Society of Human Genetics Annual Meeting attendance
Manchester, UK – 15 October 2019:Yourgene (AIM: YGEN), a leading international molecular diagnostics group, announces that it will be exhibiting at the American Society of Human Genetics (“ASHG”) Annual Meeting in Houston, Texas which runs from Tuesday 15 October to Saturday 19 October 2019 (Booth no. 101).
The ASHG Annual Meeting is the first time the Company has taken an exhibition stand since incorporating a US entity and announcing that during August 2019 Yourgene secured its first customer revenues from the USA. The Annual event attracts over 9,000 visitors and brings together researchers, academics, clinicians, laboratory practice professionals, genetic counsellors, nurses, and others with a special interest in the field of human genetics.
For more information: https://www.ashg.org/2019meeting/
The Company will be showcasing its portfolio of products and technologies and raising brand awareness of Yourgene Health as an international leader in molecular diagnostics. Attending the ASHG Annual Meeting allows the Company to meet with key suppliers and partners to enhance commercial and technical relationships, and to explore potential partnerships and collaborations to broaden the Company’s offering across reproductive health and oncology.
Yourgene Health plc
Tel: +44 (0)161 667 1053
Stifel Nicolaus Europe Limited (Sole Corporate Broker)
Tel: +44 (0)20 7710 7600
Walbrook PR Ltd (Media and Investor Relations)
Tel: +44 (0)20 7933 8780 or firstname.lastname@example.org
Mob: 07980 541 893 / 07584 391 303 / 07876 741 001
About Yourgene Health
Yourgene Health is an international molecular diagnostics group which develops and commercialises genetic products and services. The group works in partnership with global leaders in DNA technology to advance diagnostic science.
Yourgene develops and commercialises simple and accurate molecular diagnostic solutions, primarily for reproductive health. The Group’s products include non-invasive prenatal tests (NIPT) for Down’s Syndrome and other genetic disorders, Cystic Fibrosis screening tests, invasive rapid aneuploidy tests, male infertility tests and genetic disease tests. Yourgene’s commercial footprint is already established in the UK, Europe, the Middle East, Africa and Asia.
Our product development, research service and commercial capabilities extend across the lifecycle of genetic test development including regulatory submissions. Through our technical expertise and partnerships, Yourgene Health is also extending its genetic testing offering into oncology.
Yourgene Health is headquartered in Manchester, UK with offices in Taipei and Singapore, and is listed on the London Stock Exchange’s AIM market under the ticker “YGEN”. For more information, visit www.yourgene-health.com and follow us on twitter @Yourgene_Health.